Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography
Background: Diabetic macular edema (DME) can occur at any stage of non-proliferative and proliferative diabetic retinopathy. It is characterized by a swelling of the macular area that normally accounts for high-resolution visual acuity (VA), and DME therefore leads to visual deterioration. Objective...
Main Authors: | Hossam El din Khalil, Abdel Rahman Ahmed, Hassan Mahfouz Eliwa |
---|---|
Format: | Article |
Language: | English |
Published: |
Beni-Suef University, Faculty of Medicine
2022-04-01
|
Series: | Egyptian Journal of Medical Research |
Subjects: | |
Online Access: | https://ejmr.journals.ekb.eg/article_240903_0a2753be9a04b656e6d6b935081ac6fa.pdf |
Similar Items
-
Comparison between the Effect of Aflibercept (Eylea) and Ranibizumab (Lucentis) on Intraocular Pressure after 3rd Injection in Treatment of Diabetic Macular Edema
by: Hossam El Deen Khalil, et al.
Published: (2022-07-01) -
Efficacy of Aflibercept and Ranibizumab in the treatment of diabetic macular edema
by: Bing Wu, et al.
Published: (2023-08-01) -
Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
by: Murat Kucukevcilioglu, et al.
Published: (2023-01-01) -
Intravitreal Ranibizumab for Diabetic Macular Edema Patients with Good Baseline Visual Acuity: A Real-Life Study
by: Abdullah Ozkaya, et al.
Published: (2017-10-01) -
Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
by: Hiromi Ohara, et al.
Published: (2023-06-01)